Merrimack is committed to the fight against cancer. We are a science-driven community seeking to understand the complexity of the disease, engineer better solutions and deliver life-saving results for patients.
Keep an eye on our events section for dates and times.
Merrimack co-founder and MIT/Harvard professor, Michael Yaffe, recently published a perspective piece on the critical need to move beyond genomics to study the role of signaling networks in cancer. Learn more about his perspective here.
At the 2013 American Association for Cancer Research annual conference, held in Washington, D.C., we had the opportunity to show off our latest research touching on five of the six novel therapeutics we’re advancing in the clinic.
Merrimack is delighted to announce its alliance with the Pancreatic Cancer Action Network, an organization dedicated to advancing research, supporting patients and creating hope for those affected by pancreatic cancer.
MM-398, an exploratory new medicine for pancreatic cancer, is founded on a technology that allows us to increase a tumor cell's exposure to chemotherapy. Learn more about MM-398.
Professor Peter Sorger of Harvard Medical School discusses the science of systems biology and its potential impact on cancer care.
MM-121 is a novel signaling inhibitor being developed by Merrimack and Sanofi Oncology across multiple cancer indications, including breast, lung and ovarian cancer. Our research suggests that MM-121’s target, HER3, could play a substantial role in the growth and survival of cancer. Learn more about MM-121 and its clinical program here.